Track topics on Twitter Track topics that are important to you
ABIVAX Eventplan DGAP-News: ABIVAX / Schlagwort(e): Konferenz ABIVAX Eventplan 12.03.2018 / 20:30 Für den Inhalt der Mitteilung ist der Emittent verantwortlich. -----------------------------------...
Further interrogation of Phase IIa data confirms that Abivax’s potential HIV cure not only reduces viral reservoir but it also has anti-inflammatory effects. Abivax targets the immune system to figh...
Regulatory News: ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and trea...
Abivax has started patient enrolment in a Phase IIa clinical trial (ABX464-101) of its product candidate ABX464 for the treatment...Read More... The post Abivax starts enrolment in Phase IIa ulcerativ...
2017 Financial Results to be announced on March 16, 2018 Regulatory News: ABIVAX (Paris:ABVX) (Euronext Paris: FR0012333284 ABVX), a biotechnology company harnessing the immune system to develop a...
Regulatory News: ABIVAX (Euronext Paris: FR0012333284 ABVX) (Paris:ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/...
Abivax CEO Dr. Hartmut Ehrlich talks to Scrip senior editor Lucie Ellis about the progress and next development steps for...
Peer-reviewed Plenary Presentation ABX464 Reduces HIV Reservoir in Blood in Second Phase IIa Clinical Trial ABIVAX First-Ever to Show Statistically Significant (p New Anti-Inflammatory ABX464 Data...
We have published hundreds of ABIVAX news stories on BioPortfolio along with dozens of ABIVAX Clinical Trials and PubMed Articles about ABIVAX for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ABIVAX Companies in our database. You can also find out about relevant ABIVAX Drugs and Medications on this site too.